Finasteride vs Dutasteride. Which is right for your hair loss?

Quick comparison at a glance

The short version — here is how Finasteride and Dutasteride stack up on the questions most patients ask before picking one.

Finasteride

• Drug class: 5-alpha reductase inhibitor (Type II selective)
• Brand names: Propecia (1 mg), Proscar (5 mg, for BPH)
• Mechanism: Inhibits Type II 5-alpha reductase, reducing DHT formation by approximately 70% in the scalp and serum.
• Dosing: 1 mg orally once daily for male pattern hair loss (Propecia). 5 mg orally once daily for BPH (Proscar).
• Half-life: Approximately 5-6 hours.
• FDA indication: Propecia (1 mg): FDA-approved for male pattern hair loss in adult men. Proscar (5 mg): FDA-approved for benign prostatic hyperplasia.
• FDA status: FDA-approved as a finished drug product. Multiple FDA-approved generic versions available.
• Manufacturer: Merck (brand). Multiple generic manufacturers.
• Common side effects: Decreased libido, erectile dysfunction, and ejaculation disorder in a small percentage of men (reported rates roughly 2-4% in clinical trials). Breast tenderness. Post-finasteride syndrome (persistent symptoms after discontinuation) has been reported but is not fully characterized clinically.
• Typical price range: Generic finasteride is typically $15-35/month through telehealth programs. Brand Propecia is substantially more expensive.

Dutasteride

• Drug class: 5-alpha reductase inhibitor (dual Type I and Type II)
• Brand names: Avodart (0.5 mg)
• Mechanism: Inhibits both Type I and Type II 5-alpha reductase, reducing DHT formation by approximately 90% or more.
• Dosing: Off-label for hair loss: typically 0.5 mg orally once daily. FDA-approved dosing for BPH is 0.5 mg daily.
• Half-life: Approximately 5 weeks — much longer than finasteride. Significant DHT suppression persists for weeks after discontinuation.
• FDA indication: FDA-approved in the US for benign prostatic hyperplasia (BPH). NOT FDA-approved for hair loss in the US. FDA-approved for hair loss in South Korea, Japan, and some other countries.
• FDA status: FDA-approved as Avodart for BPH. Use for hair loss in the US is off-label.
• Manufacturer: GlaxoSmithKline (brand). Multiple generic manufacturers.
• Common side effects: Similar profile to finasteride — decreased libido, ED, ejaculation disorder, gynecomastia — but reported somewhat more frequently in clinical studies at equivalent hair loss dosing. The longer half-life means side effects, if they occur, may take longer to resolve after discontinuation.
• Typical price range: Generic dutasteride is typically $25-50/month through telehealth programs when prescribed off-label for hair loss.

DHT and why 5-alpha reductase matters

Male pattern hair loss (androgenetic alopecia) happens when hair follicles on the scalp are gradually miniaturized by a hormone called dihydrotestosterone, or DHT. DHT is produced from testosterone by an enzyme called 5-alpha reductase, which exists in two main forms in the body — Type I and Type II.

Hair follicles in the scalp express mostly Type II 5-alpha reductase. Blocking Type II with finasteride reduces scalp DHT enough to stop follicle miniaturization in most men, and in many men it allows some regrowth of follicles that were shrinking but not yet dormant. Blocking both Type I and Type II with dutasteride reduces DHT more completely, which can translate to better results in some patients — at the cost of more aggressive hormonal modulation and off-label status.

What the clinical trials showed

Finasteride's original hair loss trials showed that about 90% of men either stopped progression or saw some regrowth at 2 years. Placebo groups continued to lose hair. These results have been replicated many times since the original Merck trials in the 1990s.

Head-to-head comparisons of finasteride and dutasteride at hair loss dosing have shown somewhat greater regrowth with dutasteride, particularly at the crown. A notable study comparing finasteride 1 mg and dutasteride 0.5 mg over 24 weeks found dutasteride produced modestly greater improvement in hair count in the crown area. But the trial size was limited and long-term comparative safety data is less robust than for finasteride alone.

Side effects and the post-finasteride question

The side effect profiles of finasteride and dutasteride overlap substantially — both can reduce libido, affect erectile function, reduce ejaculate volume, and cause breast tenderness or gynecomastia. In clinical trials, the rates were low (typically 2-4% in finasteride trials) but real.

A more controversial topic is post-finasteride syndrome (PFS) — persistent sexual and/or neuropsychiatric symptoms after stopping finasteride. PFS is reported, but the clinical and biological mechanism is not well understood, and there is debate about how common it actually is. The FDA updated finasteride labeling in 2012 to note that sexual side effects can persist after discontinuation in some patients. A responsible prescriber discusses this explicitly before starting treatment, rather than dismissing it.

Dutasteride's longer half-life (approximately 5 weeks vs about 6 hours for finasteride) means that if side effects occur, they may take longer to clear after discontinuation. That is a real consideration for any patient who is on the fence about whether to try more aggressive 5-ARI therapy.

Practical decision framing

Finasteride typically makes sense as the first step

For most men considering oral hair loss treatment, finasteride 1 mg daily is the appropriate starting point. It is FDA-approved for this indication, has the longest track record, works for the majority of patients, and its shorter half-life makes it easier to stop if side effects occur.

Dutasteride enters the conversation later

Dutasteride is a reasonable off-label consideration for men who have been on finasteride at an adequate dose for at least 6-12 months without sufficient response, or whose hair loss is unusually aggressive. The decision is off-label and should be made with a physician who explains the tradeoff explicitly.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

Finasteride

Finasteride is the first-line, FDA-approved option for male pattern hair loss. Most men respond to it — roughly 90% of men in trials either stopped progression or saw some regrowth. It is the appropriate starting point for any man considering oral pharmacologic treatment for hair loss.

Dutasteride

Dutasteride is sometimes prescribed off-label for men who have not responded adequately to finasteride or whose hair loss is aggressive enough that more complete DHT suppression is clinically justified. The decision to use it off-label should be made with a physician who weighs the efficacy advantage against the off-label status, the longer side effect clearance time, and the higher reported side effect rate.